AICAR
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a research compound that activates AMP-activated protein kinase (AMPK)[1], earning the nickname “exercise pill” after studies showed sedentary animals given AICAR experienced dramatic endurance improvements[2]. AICAR is prohibited in sports (WADA classifies it as a metabolic modulator) and is not approved for therapeutic use in humans[1]. This educational protocol presents a once-daily subcutaneous approach for research purposes only.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once‑weekly regimen.
Research Goal: Activate AMPK pathways to mimic exercise-like metabolic effects[1][6].
Schedule: Daily subcutaneous injections for 8–12 weeks (research protocols).
Dose Range: 1,000–3,000 mcg daily (conservative); up to 5,000 mcg in advanced protocols.
Reconstitution: 3.0 mL per 50 mg vial (~16.7 mg/mL) for precise measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated 2–8 °C (35.6–46.4 °F) for up to 4 weeks[14].
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 1,000 mcg daily; increase by 1,000 mcg every 2 weeks as tolerated.
Target: 2,000–3,000 mcg daily by Weeks 3–8 (conservative).
Advanced: Up to 5,000 mcg daily if supported by protocol design.
Frequency: Once per day (subcutaneous); maintain consistent AMPK activation[3].
Timing: Any consistent time; rotate injection sites daily.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[14].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use bacteriostatic water; stable ~4 weeks[14].
Freeze–Thaw: Avoid repeated cycles; consider aliquots for long-term storage at −20 °C (−4 °F) (3–6 months)[14].
Allow vials to reach room temperature before opening to minimize condensation.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[11].
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose, administration time, and site rotation for consistency.
AICAR is prohibited by WADA and not approved for human therapeutic use[1].
How This Works
AICAR functions as an AMPK agonist, essentially mimicking an energy-depleted cellular state[6]. After administration, AICAR enters skeletal muscle and other cells where it is metabolized to ZMP (AICAR monophosphate), an analog of AMP that directly activates AMP-activated protein kinase (AMPK)[6]. AMPK serves as the master regulator of cellular energy homeostasis, and its activation stimulates glucose uptake and fatty-acid oxidation in muscle while promoting mitochondrial biogenesis to boost cellular energy output[1][6]. This metabolic shift “tricks” cells into responding as if exercising or fasting, activating pathways that improve energy metabolism and endurance capacity without actual physical activity.
Potential Benefits
Endurance Enhancement: Sedentary mice treated with AICAR showed a remarkable +44% increase in endurance without training[2], demonstrating exercise-mimetic effects.
Metabolic Improvements: Increases mitochondrial enzymes, fatty-acid oxidation capacity, and skeletal muscle glucose uptake[3][6]; improves insulin sensitivity in animal models.
Therapeutic Potential: Research suggests potential for diabetic neuropathy protection and metabolic syndrome treatment in animal models[7].
Safety Profile: Human trials (acadesine, IV) showed tolerable safety up to 210 mg/kg single dose with only mild, transient side effects[5]; research subcutaneous doses are a small fraction of this.
Side Effects: Generally well tolerated in studies; possible mild injection-site reactions (redness, irritation) with subcutaneous use.
Important: Despite promising preclinical results, AICAR remains experimental; no confirmed clinical benefit in humans has been established, and long-term risks are unknown.
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Maintain a balanced, protein-adequate diet to support metabolic adaptations.
Combine with structured exercise programs to potentially amplify AMPK-mediated benefits.
Prioritize sleep quality (7–9 hours) to optimize cellular recovery and energy metabolism.
Monitor hydration status, especially during endurance activities.
